|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Minimally invasive local therapies for liver cancer显示文摘Primary and metastatic liver tumors are an increasing global health problem,with hepatocellular carcinoma(HCC)now being the third leading cause of cancer-related mortality worldwide.Systemic treatment options for HCC remain limited,with Sorafenib as the only prospectively validated agent shown to increase overall survival.Surgical resection and/or transplantation,locally ablative therapies and regional or locoregional therapies have filled the gap in liver tumor treatments,providing improved survival outcomes for both primary and metastatic tumors.Minimally invasive local therapies have an increasing role in the treatment of both primary and metastatic liver tumors.For patients with low volume disease,these therapies have now been established into consensus practice guidelines.This review highlights technical aspects and outcomes of commonly utilized,minimally invasive local therapies including laparoscopic liver resection(LLR),radiofrequency ablation(RFA),microwave ablation(MWA),high-intensity focused ultrasound(HIFU),irreversible electroporation(IRE),and stereotactic body radiation therapy(SBRT).In addition,the role of combination treatment strategies utilizing these minimally invasive techniques is reviewed. | David Li Josephine Kang Benjamin J.Golas Vincent W.Yeung David C.Madoff | 2014 | Cancer Biology & Medicine2014，11，4： | 20 |
| 2 | Clinical practice of transarterial chemoembolization for hepatocellular carcinoma:consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology(ISMIO)显示文摘Importance:Transarterial chemoembolization(TACE)has been associated with a wide range of practice variations for hepatocellular carcinoma(HCC)between the East and the West.This considerable ambiguity may lead to the heterogeneous quality in treatment and have a negative impact on the role of TACE in the overall multidisciplinary HCC treatment system.Objective:It may be a good start to establish a guideline worldwide to have this consensus from experts who represent east and west,although it does not cover all aspects of TACE.Evidence Review:An international expert panel on TACE is convened to cluster the expert’s opinions and summary a standard consensus.This panel committee consist of leading physicians in TACE on HCC from USA,France,Japan,Singapore,Korea,China,and so on.The first-round face-to-face consensus meeting was held during in Nanjing,China in October 2019.The second-round conference for revision of the consensus was held during the Annual Meeting of Chinese College of Interventionalists in August 2020 by a hybrid format of a Webinar and roundtable meeting.After several on-line revisions,the final manuscript was approved by all members of the panel in June 2021.Findings:The consensus statements were organized into the following categories:patients’selection,performing the procedure,TACE outcomes,repeat TACE,TACE failure/refractory,and TACE-based combination treatments.Conclusions and Relevance for Reviews:More and more evidences have showed the better outcomes with strategy of combined TACE with other local therapies such as ablations.The most-recently developing strategy of combined TACE with PD-1/PD-L1 plus tyrosine kinase inhibitor(TKI)agents has shined a light to the HCC patients,especially to those with high risk of tumor recurrence after treatment or TACE failure/refractory. | Jian Lu Ming Zhao Yasuaki Arai Bin-Yan Zhong Hai-Dong Zhu Xiao-Long Qi Thierry de Baere Uei Pua Hyun Ki Yoon David C.Madoff Gao-Jun Teng International Society of Multidisciplinary Interventional Oncology(ISMIO) | 2021 | Hepatobiliary Surgery and Nutrition2021，10，5： | 9 |
| 3 | Portal vein embolization for induction of selective hepatic hypertrophy prior to major hepatectomy: rationale,techniques, outcomes and future directions显示文摘The ability to modulate the future liver remnant(FLR) is a key component of modern oncologic hepatobiliary surgery practice and has extended surgical candidacy for patients who may have been previously thought unable to survive liver resection. Multiple techniques have been developed to augment the FLR including portal vein embolization(PVE), associating liver partition and portal vein ligation(ALPPS), and the recently reported transhepatic liver venous deprivation(LVD). PVE is a well-established means to improve the safety of liver resection by redirecting blood flow to the FLR in an effort to selectively hypertrophy and ultimately improve functional reserve of the FLR. This article discusses the current practice of PVE with focus on summarizing the large number of published reports from which outcomes based practices have been developed. Both technical aspects of PVE including volumetry, approaches, and embolization agents; and clinical aspects of PVE including data supporting indications, and its role in conjunction with chemotherapy and transarterial embolization will be highlighted. PVE remains an important aspect of oncologic care; in large part due to the substantial foundation of information available demonstrating its clear clinical benefit for hepatic resection candidates with small anticipated FLRs. | David Li David C.Madoff | 2016 | Cancer Biology & Medicine2016，13，4： | 4 |
| 4 | Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors显示文摘 | KatsuhiroKobayashi SanjayGupta Jonathan C.Trent Jean‐NicolasVauthey SavitriKrishnamurthy JoeEnsor KamranAhrar Michael J.Wallace David C.Madoff RaviMurthy Stephen E.McRae Marshall E.Hicks | 2006 | Cancer2006，，12： | 1 |
| 5 | Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome显示文摘 | D.Ribero E. K.Abdalla D. C.Madoff M.Donadon E. M.Loyer J.‐N.Vauthey | 2007 | Br J Surg2007，，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员